Event > Conference >
MPS World Summit 2024
40+ international organizations and companies have teamed up for a series of annual MPS World Summits to present the latest scientific achievements, discuss the advances and challenges, and enable communication between young and newly interested scientists and pioneers of the MPS field.
In 2024, the MPS World Summit will be in Seattle, WA, USA.
Thank you for visiting us at MPS!
Educational Session
Utilizing a microphysiological system (MPS) to explore transport and metabolism through tissue barrier models
- the hands-on course will focus on:
- The importance of human-relevant models in drug transport and metabolism researchHow MPS tissue barrier models work
- What to consider when generating tissue barrier models in MPS
The trainees will learn:
- Limitations of traditional methodologies when modelling tissue barriers
- How to characterize tissue barrier maturity and functionality in the CN Bio MPS platform
- How to analyze drug transport/metabolism in the CN Bio MPS platform
Date: Monday 10 June, 2024
Time: 13:00 – 16:30
Track: 1 – Hands-On Experience
Presenters: Dr. Anthony Berger and Dr. Audrey Dubourg, CN Bio
Podium Presentation
Bridging the gap: human and preclinical animal microphysiological systems for assessing drug-induced liver injury (DILI) during drug development
Determining failure rates in the clinic due to DILI is challenging without a centralized database but estimated at 10-30%. Furthermore, the increased number of human-specific drug modalities in pipelines, bring new developmental challenges. The adoption of more advanced in vitro approaches is therefore inevitable to de-risk preclinical workflows and offset the trend towards more costly and limited animal use.
Microphysiological Systems (MPS) that mimic in vivo biology and predict drug responses bridge the gap by providing mechanistic data to refine pre-clinical in vivo experimental design and reduce the number of progressing molecules to maintain cost-effective workflows. We describe the use of PhysioMimix® OOC Systems to develop DILI assays for drug discovery and development using human, or animal liver MPS. Liver MPS, utilize perfused scaffolds to recreate 3D microtissues from primary hepatocyte and Kupffer cells that remain viable for two weeks.
Human DILI assays were developed in two formats (i) Multi-chip Liver-48 plates (48-chips) for lead optimization screening over wide concentration ranges and (ii) Multi-chip Liver-12 plates (12-chips) to unlock toxicity pathways [1, 2]. Using the latter, superior sensitivity and specificity versus 2D hepatocyte cultures and alternative 3D models was demonstrated (sensitivity 100%, accuracy 85%, and precision 100%) using reference compounds (IQ MPS Consortium). ALT levels in culture media matched clinically based severity gradings, defined by the DILI Network (DILIN), for all tested compounds. Data comparing MPS performance in Liver-12 and -48 plates will be presented.
Animal DILI assays inform the design of in vivo studies to minimize the number of animals required and predict interspecies differences. Preliminary data demonstrated superior viability and functionality compared to 2D cultures for CYP metabolism, albumin, and urea production (Multi-chip Liver-12 plate). Collectively, these data demonstrate the use of human and animal MPS to improve workflow cost effectiveness and predictivity.
Presentation from: Tomasz Kostrzewski, CN Bio
Abstract: 257
Date: Tuesday 11 June, 2024
Time: 12:20-12:40
Track: 3: Validation, qualification, meet regulatory requirements
CN Bio Posters
Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS: a promising tool for more predictive studies of human drug ADME and oral bioavailability
Poster board: 249
Abstract ID: 151
Presentation from: Audrey Dubourg, CN Bio
Date / track: Wednesday 12 June, Track 3, 16:30-18:00
Developed the model, built the assay, now a focus on throughput! A microphysiological system designed for increased reproducibility, higher-throughput and wider industry adoption – the Liver-48
Poster board: 218
Abstract ID: 346
Presentation from: Dr. Dharaminder Singh, CN Bio
Date / track: Wednesday 12 June, Track 2, 16:30-18:00
Posters citing the use of PhysioMimix OOC
Inducing perfusable microvasculature in the commercial PhysioMimix platform
Abstract ID: 324
Presentation from: Massachusettes Institute of Technology, USA
Date / track: Wednesday 12 June, Track 2, 16:30-18:00
Exploration of hepatotoxic mechanisms in human-like liver microtissues
Abstract ID: 64
Presentation from: Servier
Date / track: Thursday 13 June, Track 4, 10:00-11:30am
Microphysiological System for Predictive Genotoxicity and Mutagenicity of Drugs
Abstract ID: 663
Presentation from: Charles River Laboratories, Canada
Date / track: Thursday 13 June, Track 4, 16:30-18:00
Our Team at the MPS World Summit
Tomasz
Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was promoted to VP of Science and Technology and then to Chief Scientific Officer in 2023, with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.
Deepak
Deepak Singh joined CN Bio in February 2023. He has over 30 years of commercial experience within the life science industry, leading high-performance sales, support & marketing teams in establishing new technologies and driving global scalability of products & solutions into the markets in drug discovery, bioproduction, research and diagnostics.
Deepak was previously Head of Global Commercial at Horizon Discovery Ltd (A PerkinElmer company); VP EMEA at Pacific Biosciences; Director of EMEA Sales & Marketing at Affymetrix, and Head of UK Sales for the Genetic Analysis unit of Applied Biosystems (A Perkin-Elmer company at the time).
Audrey
Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix® OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.
Dharaminder
Dr Dharaminder Singh is an experienced Principal Bioengineer, with a background in solving Biological problems using Engineering principles. As an MPS and NAMs advocate he is part of many affiliations working to further the adoption of MPS. Having joined CN Bio in 2017 he worked to help develop the PhysioMimix® OOC technology ahead of launch in 2018. Dharaminder has since lead many collaborations including between CN Bio, Vanderbilt University and AstraZeneca, resulting in a PLOS Biology 2022 publication and further development of the technology. Dharaminder now leads the development of OOC consumable plates at CN Bio. Dharaminder graduated from The University of Sheffield with a PhD and MEng in Bioengineering.
Anthony
Dr. Anthony Berger is CN Bio’s US-based Field Application Scientist, providing support for the PhysioMimix® Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).
Dave
Dave recently joined CN Bio in February 2024 as Sales Manager for the Western U.S. Dave brings 20+ years of award-winning lab platform sales experience across several different diagnostics markets. In the past 10 years, he gained valuable experience expanding business into molecular reference labs and biotech’s in the West area. Most recently, Dave was the Regional Business Manager at Bionano Genomics selling Optical Genome Mapping on Saphyr System to Biotech’s who specialize in Cell and Gene Tx space. Dave looks forward to being a part of moving CN Bio Organ on Chip technology from start up to scale in the next few years.